Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

Is that the case? Let's look into it and decide whether the company is worth investing in.

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Therefore, I still see room for a further adjustment in the near term to the target range for the federal funds rate to move ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...